Difficulty: Medium
Average Score: 84%
Practice
The first laboratory value indication that vitamin B12 therapy is adequately treating pernicious anemia is:
Correct answer
C
Rationale
In the treatment of pernicious anemia with vitamin B12 therapy, the first laboratory value that indicates adequate treatment is when the reticulocyte count begins to rise. Reticulocytes are immature red blood cells, and an increase in their count signifies the bone marrow's response to the vitamin B12 therapy, indicating that new red blood cells are being produced. This is a critical indicator of the effectiveness of the treatment in replenishing the deficient red blood cells in pernicious anemia.
Option A, hematocrit levels rising, and Option B, hemoglobin levels returning to normal, are not the first indicators of successful treatment in pernicious anemia with vitamin B12 therapy. While these values may improve later in the treatment process as red blood cell production increases, the initial response is seen at the reticulocyte level.
Option D, vitamin B12 levels returning to normal, is also not the primary indicator of successful treatment for pernicious anemia. The focus of treatment is to address the deficiency in red blood cells caused by the inability to absorb vitamin B12, rather than solely normalizing the vitamin B12 levels in the blood.
Understanding the specific laboratory values and their significance in monitoring the response to treatment is crucial for healthcare providers managing patients with hematological disorders. Recognizing the importance of the reticulocyte count as an early indicator of treatment effectiveness in pernicious anemia can guide clinicians in assessing and adjusting therapy to optimize patient outcomes.
Option A, hematocrit levels rising, and Option B, hemoglobin levels returning to normal, are not the first indicators of successful treatment in pernicious anemia with vitamin B12 therapy. While these values may improve later in the treatment process as red blood cell production increases, the initial response is seen at the reticulocyte level.
Option D, vitamin B12 levels returning to normal, is also not the primary indicator of successful treatment for pernicious anemia. The focus of treatment is to address the deficiency in red blood cells caused by the inability to absorb vitamin B12, rather than solely normalizing the vitamin B12 levels in the blood.
Understanding the specific laboratory values and their significance in monitoring the response to treatment is crucial for healthcare providers managing patients with hematological disorders. Recognizing the importance of the reticulocyte count as an early indicator of treatment effectiveness in pernicious anemia can guide clinicians in assessing and adjusting therapy to optimize patient outcomes.